Jump to content

25H-NBOMe

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 11:50, 7 May 2017 (image). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

25H-NBOMe
Clinical data
ATC code
  • none
Identifiers
  • 2-(2,5-Dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC18H23NO3
Molar mass301.386 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1)OC)CCNCC2=CC=CC=C2OC
  • InChI=1S/C18H23NO3/c1-20-16-8-9-18(22-3)14(12-16)10-11-19-13-15-6-4-5-7-17(15)21-2/h4-9,12,19H,10-11,13H2,1-3H3
  • Key:RMLXCDMTGWSEOU-UHFFFAOYSA-N

25H-NBOMe (NBOMe-2C-H) is a derivative of the phenethylamine hallucinogen 2C-H, which acts as a highly potent partial agonist for the human 5-HT2A receptor.[1]

Legality

Sweden

The Riksdag added 25H-NBOMe to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 1, 2013, published by Medical Products Agency (MPA) in regulation LVFS 2013:15 listed as 25H-NBOMe, and 2-(2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin.[2]

See also

References